PROSCA/BLADDR 2022 | Potential of platinum-free treatment approaches in patients with mUC

Aristotelis Bamias, MD, University of Athens, Athens, Greece, outlines the possibility of platinum-free approaches in patients with metastatic urothelial carcinoma (mUC), highlighting the importance of cisplatin-based chemotherapy in patients with mUC where it remains a standard. Dr Bamias discusses the potential of combination approaches involving cisplatin-based chemotherapy. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.